data + articles · 1 listed
newest 2014spec sheet6 rows
Tandospirone is a case of a drug that succeeded, just never where most of the archive's audience would notice; the azapirone was approved and marketed in Japan in 1996 as Sediel for generalized anxiety disorder, and later in China in 2004, where it remains in clinical use today for anxiety and, off-label, mood and psychotic-adjunct indications. It never sought FDA approval and stayed almost entirely off the radar in the US and Europe, overshadowed first by benzodiazepines and later by SSRIs. Its main pharmacological claim to fame is being one of the most selective 5-HT1A partial agonists among the azapirones, with comparatively little dopamine D2 or off-target receptor activity compared to relatives like buspirone.
- non-sedating anxiolytic effect used clinically in Japan and China since the mid-1990s
- high 5-HT1A selectivity relative to other azapirones like buspirone
- preclinical evidence of increased hippocampal neurogenesis with chronic dosing
- dizziness and nausea reported, consistent with other 5-HT1A partial agonists
- Tandospirone has been a routinely prescribed anxiety medication in Japan since 1996, yet it remains essentially unknown to most Western prescribers and patients.
Mechanism
Partial at the receptor, an azapirone with high selectivity for 5-HT1A over other serotonin receptor subtypes and the receptor compared to buspirone.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Nothing in the azapirone class produces benzodiazepine-style dependence, and tandospirone is no exception: no meaningful sedation, no tolerance, no withdrawal. What patients report is dizziness, nausea, drowsiness and headache, usually mild. Japanese labelling flags two rare but serious reactions, serotonin syndrome and neuroleptic malignant syndrome, and the first is the practical one, because the risk climbs alongside MAOIs, SSRIs and other serotonergic drugs. Caution applies with significant liver or kidney impairment. Its slow two to four week onset makes it useless for acute panic, which is where people escalate rather than wait.
History
Developed by Sumitomo Pharmaceuticals in Japan; approved and marketed as Sediel in Japan in 1996 for generalized anxiety disorder, and approved in China in 2004. It has never been submitted for FDA approval and remains essentially unavailable in the US and Europe.
Subjective profileweighing the evidence above
A real, still-prescribed anxiolytic in Japan and China that simply never made the leap to Western markets, making it a genuine East-West blind spot rather than a failed drug.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is tandospirone available in the US?
No. It has never been submitted for FDA approval and is not available through normal US pharmacy channels; it remains a Japan- and China-market drug.
How does tandospirone compare to buspirone?
Both are azapirone 5-HT1A partial agonists, but tandospirone is considered more selective for 5-HT1A with less dopamine D2 receptor activity than buspirone.
Limitations of the evidence
- never evaluated by the FDA, so Western safety and interaction data is limited
Adverse effects
- dizziness and nausea reported, consistent with other 5-HT1A partial agonists